145 related articles for article (PubMed ID: 22977617)
21. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
22. Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor.
Kogo M; Shimizu R; Uehara K; Takahashi Y; Kokubo M; Imai Y; Tomii K
Lung Cancer; 2015 Nov; 90(2):364-8. PubMed ID: 26384434
[TBL] [Abstract][Full Text] [Related]
23. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases.
Travis WD; Linnoila RI; Tsokos MG; Hitchcock CL; Cutler GB; Nieman L; Chrousos G; Pass H; Doppman J
Am J Surg Pathol; 1991 Jun; 15(6):529-53. PubMed ID: 1709558
[TBL] [Abstract][Full Text] [Related]
24. Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with
Muto S; Ozaki Y; Okabe N; Matsumura Y; Hasegawa T; Shio Y; Hashimoto Y; Suzuki H
Case Rep Oncol; 2020; 13(3):1387-1392. PubMed ID: 33442360
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing.
Ito M; Miyata Y; Hirano S; Kimura S; Irisuna F; Ikeda K; Kushitani K; Tsutani Y; Ueda D; Tsubokawa N; Takeshima Y; Okada M
Oncotarget; 2017 Dec; 8(65):108936-108945. PubMed ID: 29312580
[TBL] [Abstract][Full Text] [Related]
26. Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.
Simbolo M; Barbi S; Fassan M; Mafficini A; Ali G; Vicentini C; Sperandio N; Corbo V; Rusev B; Mastracci L; Grillo F; Pilotto S; Pelosi G; Pelliccioni S; Lawlor RT; Tortora G; Fontanini G; Volante M; Scarpa A; Bria E
J Thorac Oncol; 2019 Sep; 14(9):1651-1661. PubMed ID: 31085341
[TBL] [Abstract][Full Text] [Related]
27. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
[TBL] [Abstract][Full Text] [Related]
28. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
[TBL] [Abstract][Full Text] [Related]
29. Gynecologic large cell neuroendocrine carcinoma: A review.
Burkeen G; Chauhan A; Agrawal R; Raiker R; Kolesar J; Anthony L; Evers BM; Arnold S
Rare Tumors; 2020; 12():2036361320968401. PubMed ID: 33194158
[TBL] [Abstract][Full Text] [Related]
30. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.
Lei L; Jiang Z; Zhang G; Cheng Q; Lu H
World J Surg Oncol; 2018 Jun; 16(1):110. PubMed ID: 29914531
[TBL] [Abstract][Full Text] [Related]
31. Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population.
Pala EE; Bayol U; Keskin EU; Ozguzer A; Kucuk U; Ozer O; Koc A
Pathol Oncol Res; 2015 Sep; 21(4):1223-7. PubMed ID: 26060045
[TBL] [Abstract][Full Text] [Related]
32. Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?
Derks JL; Dingemans AC; van Suylen RJ; den Bakker MA; Damhuis RAM; van den Broek EC; Speel EJ; Thunnissen E
Histopathology; 2019 Mar; 74(4):555-566. PubMed ID: 30485478
[TBL] [Abstract][Full Text] [Related]
33. Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401).
Kawabe T; Yamamoto M; Sato Y; Yomo S; Kondoh T; Nagano O; Serizawa T; Tsugawa T; Okamoto H; Akabane A; Aita K; Sato M; Jokura H; Kawagishi J; Shuto T; Kawai H; Moriki A; Kenai H; Iwai Y; Gondo M; Hasegawa T; Yasuda S; Kikuchi Y; Nagatomo Y; Watanabe S; Hashimoto N
J Neurosurg; 2016 Dec; 125(Suppl 1):11-17. PubMed ID: 27903179
[TBL] [Abstract][Full Text] [Related]
34. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.
Fasano M; Della Corte CM; Papaccio F; Ciardiello F; Morgillo F
J Thorac Oncol; 2015 Aug; 10(8):1133-41. PubMed ID: 26039012
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of YAP1 expression and its association with neuroendocrine markers in resected pulmonary large cell neuroendocrine carcinoma (LCNEC).
Sun X; Zhang J; Dong J; Liu L; Li X; Xing P; Ying J; Che Y; Li J; Yang L
Transl Oncol; 2022 Nov; 25():101538. PubMed ID: 36103754
[TBL] [Abstract][Full Text] [Related]
37. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
Gilbert JA; Goetz MP; Reynolds CA; Ingle JN; Giordano KF; Suman VJ; Blair HE; Jenkins RB; Lingle WL; Reinholz MM; Adjei AA; Ames MM
Mol Cancer Ther; 2008 Apr; 7(4):944-51. PubMed ID: 18413808
[TBL] [Abstract][Full Text] [Related]
38. Molecular Classification of Neuroendocrine Tumors of the Thymus.
Dinter H; Bohnenberger H; Beck J; Bornemann-Kolatzki K; Schütz E; Küffer S; Klein L; Franks TJ; Roden A; Emmert A; Hinterthaner M; Marino M; Brcic L; Popper H; Weis CA; Pelosi G; Marx A; Ströbel P
J Thorac Oncol; 2019 Aug; 14(8):1472-1483. PubMed ID: 31042566
[TBL] [Abstract][Full Text] [Related]
39. Tropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma.
Odate S; Onishi H; Nakamura K; Kojima M; Uchiyama A; Kato M; Katano M
Anticancer Res; 2013 Sep; 33(9):3699-703. PubMed ID: 24023298
[TBL] [Abstract][Full Text] [Related]
40. Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
Zhou F; Hou L; Ding T; Song Q; Chen X; Su C; Li W; Gao G; Ren S; Wu F; Fan J; Wu C; Zhang J; Zhou C
Lung Cancer; 2018 Feb; 116():30-37. PubMed ID: 29413048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
